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background: Familial hypercholesterolemia (FH) accelerates carotid intima media thickness (c-IMT) which is a surrogate marker for 
cardiovascular (CV) disease. This study investigated the effect of rosuvastatin on c-IMT in FH children 6-17 years compared with unaffected (non-FH) 
matched siblings. Trial number: NCT01078675.
methods: Children with FH and LDL-C >190 mg/dL or >158 mg/dL plus other CV risk factors were included. FH children aged 6-9 were statin 
naïve. All received rosuvastatin 5 mg once daily, with up-titration to 10 mg (aged 6-9) or 20 mg (aged 10-17) based on LDL-C achieved. c-IMT was 
assessed at baseline, and 12 and 24 months in all FH children, and in ≥60 matched unaffected siblings.
results: 197 FH children and 65 unaffected siblings were included in the intent to treat population. The average mean c-IMT (mm) was higher for 
FH children vs unaffected siblings at baseline (0.398 vs 0.376), slightly higher at 12 months (0.402 vs 0.390), and similar at 24 months (0.409 vs 
0.402). The average mean cIMT increased in the first and second years, with numerically less increase in the treated FH children than the unaffected 
siblings (figure), with similar findings for subgroups aged 6-9 and 14-17. The changes over time were not statistically significant.
conclusion: In FH children aged 6-17, rosuvastatin 5-20 mg did not significantly affect mean c-IMT over 24 months. However, there was a trend for 
slowing of thickening of c-IMT with rosuvastatin-treatment compared with unaffected siblings.
